Frontiers of Medicine

, Volume 7, Issue 3, pp 290–300

Therapeutic effects of thalidomide in hematologic disorders: a review



The extensive autoimmune, anti-inflammatory, and anticancer applications of thalidomide have inspired a growing number of studies and clinical trials. As an inexpensive agent with relatively low toxicity, thalidomide is regarded as a promising therapeutic candidate, especially for malignant diseases. We review its therapeutic effects in hematology, including those on multiple myeloma, Waldenstroem macroglobulinemia, lymphoma, mantle-cell lymphoma, myelodysplastic syndrome, hereditary hemorrhagic telangiectasia, and graftversus-host disease. Most studies have shown satisfactory results, although several have reported the opposite. Aside from optimal outcomes, the toxicities and adverse effects of thalidomide should also be examined. The current work includes a discussion of the mechanisms through which the novel biological effects of thalidomide occur, although more studies should be devoted to this aspect. With appropriate safeguards, thalidomide may benefit patients suffering from a broad variety of disorders, particularly refractory and resistant diseases.


thalidomide multiple myeloma lymphoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363(9423): 1802–1811PubMedCrossRefGoogle Scholar
  2. 2.
    Wood AJJ, Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330(7): 484–489CrossRefGoogle Scholar
  3. 3.
    Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists’ Collaborative Group. J Clin Oncol 1998; 16(12): 3832–3842Google Scholar
  4. 4.
    Vacca A, Loreto MD, Ribatti D, Stefano RD, Gadaleta-Caldarola G, Iodice G, Caloro D, Dammacco F. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol 1995; 50(1): 9–14PubMedCrossRefGoogle Scholar
  5. 5.
    Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87(3): 503–508PubMedCrossRefGoogle Scholar
  6. 6.
    Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101(6): 2144–2151PubMedCrossRefGoogle Scholar
  7. 7.
    Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341(21): 1565–1571PubMedCrossRefGoogle Scholar
  8. 8.
    Suzuki K. Current therapeutic strategy for multiple myeloma. Jpn J Clin Oncol 2013; 43(2): 116–124PubMedCrossRefGoogle Scholar
  9. 9.
    Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G. Advances in biology and therapy of multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2003; 2003(1): 248–278CrossRefGoogle Scholar
  10. 10.
    Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2(12): 927–937PubMedCrossRefGoogle Scholar
  11. 11.
    Richardson P, Anderson K. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma. J Clin Oncol 2006; 24(3): 334–336PubMedCrossRefGoogle Scholar
  12. 12.
    Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96(9): 2943–2950PubMedGoogle Scholar
  13. 13.
    De Sanctis JB, Mijares M, Suárez A, Compagnone R, Garmendia J, Moreno D, Salazar-Bookaman M. Pharmacological properties of thalidomide and its analogues. Recent Pat Inflamm Allergy Drug Discov 2010; 4(2): 144–148PubMedCrossRefGoogle Scholar
  14. 14.
    Drucker L, Uziel O, Tohami T, Shapiro H, Radnay J, Yarkoni S, Lahav M, Lishner M. Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma. Mol Pharmacol 2003; 64(2): 415–420PubMedCrossRefGoogle Scholar
  15. 15.
    D’Amato RJ, Lentzsch S, Anderson KC, Rogers MS. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol 2001; 28(6): 597–601PubMedCrossRefGoogle Scholar
  16. 16.
    Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354(10): 1021–1030PubMedCrossRefGoogle Scholar
  17. 17.
    Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24 (3): 431–436PubMedCrossRefGoogle Scholar
  18. 18.
    Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst H, Sonneveld P; Dutch-Belgium Cooperative Group HOVON. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 2010; 28(19): 3160–3166PubMedCrossRefGoogle Scholar
  19. 19.
    Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, Testoni N, Tonelli M, de Vivo A, Palareti G, Tura S, Baccarani M. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89(7): 826–831PubMedGoogle Scholar
  20. 20.
    Bladé J, Rosiñol L. Advances in therapy of multiple myeloma. Curr Opin Oncol 2008; 20(6): 697–704PubMedCrossRefGoogle Scholar
  21. 21.
    Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S; International Myeloma Working Group. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117(23): 6063–6073PubMedCrossRefGoogle Scholar
  22. 22.
    Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012; 97(3): 442–450PubMedCrossRefGoogle Scholar
  23. 23.
    Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pégourié B, Kolb B, Stoppa AM, Fuzibet JG, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traullé C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau JL. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011; 118(22): 5752–5758, quiz 5982PubMedCrossRefGoogle Scholar
  24. 24.
    Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012; 119(1): 7–15PubMedCrossRefGoogle Scholar
  25. 25.
    Broyl A, Kuiper R, van Duin M, van der Holt B, el Jarari L, Bertsch U, Zweegman S, Buijs A, Hose D, Lokhorst HM, Goldschmidt H, Sonneveld P; Dutch-Belgian HOVON group; German GMMG Group. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013; 121 (4): 624–627PubMedCrossRefGoogle Scholar
  26. 26.
    Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013; 121(6): 884–892PubMedCrossRefGoogle Scholar
  27. 27.
    Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, Dimopoulos MA. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003; 30(2): 110–115PubMedCrossRefGoogle Scholar
  28. 28.
    Leleu X, Gay J, Roccaro AM, Moreau AS, Poulain S, Dulery R, Champs BB, Robu D, Ghobrial IM. Update on therapeutic options in Waldenström macroglobulinemia. Eur J Haematol 2009; 82(1): 1–12PubMedCrossRefGoogle Scholar
  29. 29.
    Dimopoulos MA, Anagnostopoulos A. Treatment of Waldenstrom’s macroglobulinemia. Curr Treat Options Oncol 2007; 8(2): 144–153PubMedCrossRefGoogle Scholar
  30. 30.
    Gertz MA. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87(5): 503–510PubMedCrossRefGoogle Scholar
  31. 31.
    Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, Briccetti FM, Pasmantier M, Zimbler H, Cooper RB, Moore M, Hill J 2nd, Rauch A, Garbo L, Chu L, Chua C, Nantel SH, Lovett DR, Boedeker H, Sonneborn H, Howard J, Musto P, Ciccarelli BT, Hatjiharissi E, Anderson KC. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 112(12): 4452–4457PubMedCrossRefGoogle Scholar
  32. 32.
    Johnson SA, Birchall J, Luckie C, Oscier DG, Owen RG; Haemato-Oncology Task Force of the British Committee for Standards in Haematology. Guidelines on the management of Waldenström macroglobulinaemia. Br J Haematol 2006; 132(6): 683–697PubMedCrossRefGoogle Scholar
  33. 33.
    Kawano Y, Nakama T, Hata H, Kimura E, Maruyoshi N, Uchino M, Mitsuya H. Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. J Neurol Sci 2010; 297(1–2): 101–104PubMedCrossRefGoogle Scholar
  34. 34.
    Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 2003; 21(4): 607–614PubMedCrossRefGoogle Scholar
  35. 35.
    Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology (Am Soc Hematol Educ Program) 2009; 2009(1): 497–506CrossRefGoogle Scholar
  36. 36.
    García-Sanz R, González-López TJ, Vázquez L, Hermida G, Graciani IF, San Miguel JF. The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin’s lymphoma. Eur J Haematol 2010; 84(3): 266–270PubMedCrossRefGoogle Scholar
  37. 37.
    Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD; Cancer and Leukemia Group B. Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol 2008; 140(3): 313–319PubMedCrossRefGoogle Scholar
  38. 38.
    Kuruvilla J, Song K, Mollee P, Panzarella T, McCrae J, Nagy T, Crump M, Keating A. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin’s lymphoma. Hematology 2006; 11(1): 25–29PubMedCrossRefGoogle Scholar
  39. 39.
    Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma 2008; 49(7): 1238–1245PubMedCrossRefGoogle Scholar
  40. 40.
    Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999; 36(2): 115–127PubMedGoogle Scholar
  41. 41.
    Zhou Y, Zhang L, Romaguera J, Delasalle K, Han X, Du X, Kwak L, Yi Q, Wang M. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol 2008; 83(2): 144–149PubMedCrossRefGoogle Scholar
  42. 42.
    Damaj G, Lefrère F, Delarue R, Varet B, Furman R, Hermine O. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 2003; 17(9): 1914–1915PubMedCrossRefGoogle Scholar
  43. 43.
    Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, Elstrom R, Lachs M, Hajjar KA, Leonard JP. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 2010; 116(11): 2655–2664PubMedCrossRefGoogle Scholar
  44. 44.
    Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol 2009; 27(32): 5404–5409PubMedCrossRefGoogle Scholar
  45. 45.
    Tueger S, Chen FE, Ahsan G, McDonald V, Andrews VE, Madrigal JA, Kazmi MA. Thalidomide induced remission of refractory diffuse large B-Cell lymphoma post-allogeneic SCT. Haematologica 2006; 91(4): e49–e50Google Scholar
  46. 46.
    Ramasamy K, Lim Z, Pagliuca A, Salisbury JR, Mufti GJ, Devereux S. Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. Haematologica 2006; 91(1): 117–118Google Scholar
  47. 47.
    Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998; 83(1): 71–86PubMedGoogle Scholar
  48. 48.
    Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 2008; 87(9): 691–699PubMedCrossRefGoogle Scholar
  49. 49.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51(2): 189–199PubMedGoogle Scholar
  50. 50.
    Warlick ED. Epidemiology of myelodysplastic syndromes: many questions remain. Leuk Lymphoma 2011; 52(2): 163–164PubMedCrossRefGoogle Scholar
  51. 51.
    Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002; 16(1): 1–6PubMedCrossRefGoogle Scholar
  52. 52.
    Invernizzi R, Travaglino E, Amici MD, Brugnatelli S, Ramajoli I, Rovati B, Benatti C, Ascari E. Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes. Leuk Res 2005; 29(6): 641–647PubMedCrossRefGoogle Scholar
  53. 53.
    Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J. Thalidomide produces transfusion independence in longstanding refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98(4): 958–965PubMedCrossRefGoogle Scholar
  54. 54.
    Chung CY, Lin SF, Chen PM, Chang MC, Kao WY, Chao TY, Hsiao LT, Yen CC, Yang MH, Hwang WS, Lin TL, Chiou TJ, Chang CS. Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: results of a phase II trial. Anticancer Res 2012; 32(8): 3415–3419PubMedGoogle Scholar
  55. 55.
    Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O’Brien S, Keating M, Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2003; 97(5): 1234–1241PubMedCrossRefGoogle Scholar
  56. 56.
    Musto P, Falcone A, Sanpaolo G, Bodenizza C. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes. Leuk Res 2006; 30(4): 385–388PubMedCrossRefGoogle Scholar
  57. 57.
    Leitch HA, Buckstein R, Shamy A, Storring JM. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline. Crit Rev Oncol Hematol 2013; 85(2): 162–192PubMedCrossRefGoogle Scholar
  58. 58.
    Olitsky SE. Hereditary hemorrhagic telangiectasia: diagnosis and management. Am Fam Physician 2010; 82(7): 785–790PubMedGoogle Scholar
  59. 59.
    Davidson TM, Olitsky SE, Wei JL. Hereditary hemorrhagic telangiectasia/avastin. Laryngoscope 2010; 120(2): 432–435PubMedGoogle Scholar
  60. 60.
    Kurstin R. Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease. Oncology (Williston Park) 2002; 16(1): 21–24Google Scholar
  61. 61.
    Pérez-Encinas M, Rabuñal Martínez MJ, Bello López JL. Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia? Haematologica 2002; 87 (8): ELT34PubMedGoogle Scholar
  62. 62.
    Franchini M, Frattini F, Crestani S, Bonfanti C. Novel treatments for epistaxis in hereditary hemorrhagic telangiectasia: a systematic review of the clinical experience with thalidomide. J Thromb Thrombolysis 2012 Nov 11. [Epub ahead of print] doi: 10.1007/s11239-012-0840-5Google Scholar
  63. 63.
    Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, Bréant C, Mathivet T, Larrivée B, Thomas JL, Arthur HM, Westermann CJ, Disch F, Mager JJ, Snijder RJ, Eichmann A, Mummery CL. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16(4): 420–428PubMedCrossRefGoogle Scholar
  64. 64.
    Lim SH, McWhannell A, Vora AJ, Boughton BJ. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation. Lancet 1988; 331(8577): 117CrossRefGoogle Scholar
  65. 65.
    Vogelsang GB, Hess AD, Santos GW. Thalidomide for treatment of graft-versus-host disease. Bone Marrow Transplant 1988; 3(5): 393–398PubMedGoogle Scholar
  66. 66.
    Vogelsang GB, Hess AD, Gordon G, Santos GW. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transplantation 1986; 41(5): 644–647PubMedCrossRefGoogle Scholar
  67. 67.
    Heney D, Norfolk DR, Wheeldon J, Bailey CC, Lewis IJ, Barnard DL. Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol 1991; 78(1): 23–27PubMedCrossRefGoogle Scholar
  68. 68.
    Browne PV, Weisdorf DJ, DeFor T, Miller WJ, Davies SM, Filipovich A, McGlave PB, Ramsay NK, Wagner J, Enright H. Response to thalidomide therapy in refractory chronic graft-versushost disease. Bone Marrow Transplant 2000; 26(8): 865–869PubMedCrossRefGoogle Scholar
  69. 69.
    Cole CH, Rogers PC, Pritchard S, Phillips G, Chan KW. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Bone Marrow Transplant 1994; 14(6): 937–942PubMedGoogle Scholar
  70. 70.
    Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Appelbaum FR, Storb R, Martin PJ. Thalidomide for treatment of patients with chronic graft-versushost disease. Blood 2000; 96(12): 3995–3996PubMedGoogle Scholar
  71. 71.
    Arora M, Wagner JE, Davies SM, Blazar BR, Defor T, Enright H, Miller WJ, Weisdorf DF. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001; 7(5): 265–273PubMedCrossRefGoogle Scholar
  72. 72.
    Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Horton C, Atra A, Ortin M, Rudin C, Goyal S, Sankpal S, Meller S, Pinkerton CR, Mehta J, Singhal S. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 2003; 32(2): 165–170PubMedCrossRefGoogle Scholar
  73. 73.
    Ito T, Ando H, Handa H. Teratogenic effects of thalidomide: molecular mechanisms. Cell Mol Life Sci 2011; 68(9): 1569–1579PubMedCrossRefGoogle Scholar
  74. 74.
    Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 2013; 4 (4): 83–687Google Scholar
  75. 75.
    Stephens TD, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 2000; 59(12): 1489–1499PubMedCrossRefGoogle Scholar
  76. 76.
    Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117(7): 508–515PubMedCrossRefGoogle Scholar
  77. 77.
    van Heeckeren WJ, Sanborn SL, Narayan A, Cooney MM, McCrae KR, Schmaier AH, Remick SC. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol 2007; 14(5): 468–480PubMedCrossRefGoogle Scholar
  78. 78.
    Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc 2005; 80(12): 1549–1551PubMedCrossRefGoogle Scholar
  79. 79.
    Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002; 13(7): 1029–1035PubMedCrossRefGoogle Scholar
  80. 80.
    Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20(21): 4319–4323PubMedCrossRefGoogle Scholar
  81. 81.
    Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22(13): 2532–2539PubMedCrossRefGoogle Scholar
  82. 82.
    Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multiinstitutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 2002; 95(8): 1629–1636PubMedCrossRefGoogle Scholar
  83. 83.
    Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22(2): 414–423PubMedCrossRefGoogle Scholar
  84. 84.
    Ikhlaque N, Seshadri V, Kathula S, Baumann MA. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol 2006; 81(6): 420–422PubMedCrossRefGoogle Scholar
  85. 85.
    Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100(4): 1168–1171PubMedCrossRefGoogle Scholar
  86. 86.
    Silingardi M, Iotti M, Trenti C, Salvarani C, Iori I. Thalidomide, deep venous thrombosis and vasculitis. J Thromb Haemost 2004; 2 (11): 2062–2063PubMedCrossRefGoogle Scholar
  87. 87.
    Antoine JC, Camdessanché JP. Peripheral nervous system involvement in patients with cancer. Lancet Neurol 2007; 6(1): 75–86PubMedCrossRefGoogle Scholar
  88. 88.
    Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Ther 2003; 25(2): 342–395PubMedCrossRefGoogle Scholar
  89. 89.
    Mazumder A, Jagannath S. Thalidomide and lenalidomide in multiple myeloma. Best Pract Res Clin Haematol 2006; 19(4): 769–780PubMedCrossRefGoogle Scholar
  90. 90.
    Hafström T. Polyneuropathy after neurosedyn (thalidomide) and its prognosis. Acta Neurol Scand 1967; 43(Suppl 32): 31–41Google Scholar
  91. 91.
    Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O’Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002; 59(12): 1872–1875PubMedCrossRefGoogle Scholar
  92. 92.
    Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol 2003; 1(3): 194–205PubMedGoogle Scholar
  93. 93.
    Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13(1): 27–46PubMedCrossRefGoogle Scholar
  94. 94.
    Giannini F, Volpi N, Rossi S, Passero S, Fimiani M, Cerase A. Thalidomide-induced neuropathy: a ganglionopathy? Neurology 2003; 60(5): 877–878PubMedCrossRefGoogle Scholar
  95. 95.
    Briani C, Zara G, Rondinone R, Della Libera S, Ermani M, Ruggero S, Ghirardello A, Zampieri S, Doria A. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology 2004; 62(12): 2288–2290PubMedCrossRefGoogle Scholar
  96. 96.
    Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001; 24(8): 1050–1057PubMedCrossRefGoogle Scholar
  97. 97.
    Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21(1): 16–19PubMedCrossRefGoogle Scholar
  98. 98.
    Curley MJ, Hussein SA, Hassoun PM. Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. J Clin Microbiol 2002; 40(6): 2302–2304PubMedCrossRefGoogle Scholar
  99. 99.
    Prasad HK, Kaushal V, Mehta P. Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature. Am J Hematol 2007; 82(9): 855–857PubMedCrossRefGoogle Scholar
  100. 100.
    Duyvendak M, Naunton M, Kingma BJ, Brouwers JR. Thalidomide-associated thrombocytopenia. Ann Pharmacother 2005; 39(11): 1936–1939PubMedCrossRefGoogle Scholar
  101. 101.
    Eo WK, Kim SH, Cheon SH, Lee SH, Jeong JS, Kim YS, Chang HK, Suh KS, Kim HY. Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report. Ann Hematol 2010; 89(4): 421–422PubMedCrossRefGoogle Scholar
  102. 102.
    Harris E, Behrens J, Samson D, Rahemtulla A, Russell NH, Byrne JL. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 2003; 122(1): 160–161PubMedCrossRefGoogle Scholar

Copyright information

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of Hematology, Qilu HospitalShandong UniversityJinanChina
  2. 2.Shandong University School of MedicineJinan, ShandongChina
  3. 3.Department of General Surgery, Qilu HospitalShandong UniversityJinanChina

Personalised recommendations